Dawn Wilson Selected Research

Pericardial Effusion

7/2017

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dawn Wilson Research Topics

Disease

2	Edema (Dropsy) 07/2017 - 01/2014
2	Disease Progression 07/2017 - 01/2014
2	Neoplasms (Cancer) 07/2017 - 01/2014
2	Fatigue 07/2017 - 01/2014
2	Anemia 01/2014 - 11/2013
1	Neuromuscular Diseases (Neuromuscular Disease) 01/2018
1	Pericardial Effusion 07/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 07/2017
1	Epistaxis (Nosebleed) 07/2017
1	Telangiectasis (Telangiectasia) 07/2017
1	Diarrhea 07/2017
1	Squamous Cell Carcinoma of Head and Neck 12/2016

Drug/Important Bio-Agent (IBA)

3	human ALK1-Fc fusion proteinIBA 07/2017 - 01/2014
2	LigandsIBA 12/2016 - 01/2014
2	Activin Receptors (Activin Receptor)IBA 12/2016 - 01/2014
1	FollistatinIBA 01/2018
1	MyostatinIBA 01/2018
1	Tyrosine Kinase InhibitorsIBA 07/2017
1	Axitinib (AG 013736)IBA 07/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2017
1	PlatinumIBA 12/2016
1	DiureticsIBA 01/2014
1	ACE-011IBA 11/2013

Therapy/Procedure

1	Therapeutics 01/2014